Mountain View Clinical Research, Inc.

Greer, South Carolina 29651

0 studies enrolling now · 17 studies all time

What they study most

Albuminuria, Arthritis, Rheumatoid, Aura, Cardiovascular Disease, Chronic Obstructive Pulmonary Disease, Diabetes Mellitus, Type 1, Diabetic Nephropathy, Dyslipidemia, Irritable Bowel Syndrome Characterized by Constipation, Irritable Bowel Syndrome With Diarrhea (IBS-D), Migraine, Migraine Disorders

Studies at this site

• Pemafibrate to Reduce Cardiovascular OutcoMes by Reducing Triglycerides IN patiENts With diabeTes (PROMINENT) — Stopped early
• A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight — Completed
• Mylan Insulin Aspart Study — Completed
• A Study of Tirzepatide (LY3298176) Once a Week Versus Insulin Glargine Once a Day in Participants With Type 2 Diabetes and Increased Cardiovascular Risk — Completed
• A Study of MD-7246 to Treat Abdominal Pain in Patients With Diarrhea-predominant Irritable Bowel Syndrome — Completed
• Prospective Randomized Evaluation Of Celecoxib Integrated Safety Vs Ibuprofen Or Naproxen — Completed
• A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation (IBS-C) — Completed
• An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine — Completed
• A Study of LY2623091 in Participants With High Blood Pressure — Completed
• Evaluation of Efficay & Safety of Galcanezumab in the Prevention of Episodic Migraine- the EVOLVE-2 Study — Completed
• A Study to Assess the Efficacy and Safety of Oral CL-H1T in the Treatment of Acute Migraine Pain — Completed
• Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute Treatment of Migraine — Completed
• The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects — Stopped early
• A Study to Evaluate the Analgesic Efficacy and Safety of V120083 in Subjects With Osteoarthritis (OA) of the Knee — Completed
• The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects — Stopped early
• Safety Study of Arformoterol Tartrate Inhalation Solution in Chronic Obstructive Pulmonary Disease (COPD) Subjects — Completed
• Study of XL784 in Patients With Albuminuria Due to Diabetic Nephropathy — Completed